Videos

The rationale for treating steroid-refractory acute graft-versus-host disease with ruxolitinib, a JAK inhibitor, and recommendations for monitoring and managing treatment-related adverse events.

Dr Michael Bishop, of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, describes the rationale for the design of the phase 3 REACH2 trial in steroid-refractory acute graft-versus-host disease and provides perspective on important takeaways from data presented.

Considerations for assessing response to steroid therapy as initial therapy for acute graft-versus-host disease and factors that impact next-line therapy, when necessary.

Michael Bishop, MD, shares recommendations that can help hematologists/oncologists appropriately identify patients with steroid-refractory acute graft-versus-host disease and describes how his treatment approaches differ based on grade.

Criteria used by hematologists/oncologists to diagnose acute graft-versus-host disease (GVHD), and common therapies used for GVHD prevention in patients who receive hematopoietic stem cell transplantation.

Michael Bishop, MD, discusses his concerns for a 53-year-old man diagnosed with acute graft-versus-host disease later deemed as steroid refractory, based on the typical prognosis for patients in similar scenarios.

Recommendations for using ruxolitinib to treat a 53-year-old patient with acute graft-versus-host disease whose disease progresses following previous treatment with steroid therapy.

Shannon Westin, MD, MPH, FACOG, discusses the rationale of using durvalumab, a PD-L1 inhibitor, with or without olaparib.

Naveen Pemmaraju, MD, discusses the results of combining ruxolitinib and navitoclax in different high-risk populations of relapsed/refractory myelofibrosis.

Andre Goy, MD, MS, discusses the results of the ZUMA-2 study of the chimeric antigen receptor T-cell therapy

Neeraj Agarwal, MD, discusses the possible adverse events of the randomized phase 3 CONTACT-02 trial of cabozantinib plus atezolizumab versus a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

Sairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.

Dr John P. Leonard highlights ongoing clinical trials and therapies of interest in the follicular lymphoma pipeline and explains how progress in the field will help address ongoing treatment challenges.

John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian Hospital, comments on the safety and efficacy data for PI3K inhibitors for relapsed/refractory follicular lymphoma treatment and shares advice on best practices for monitoring patients on therapy and managing any treatment-related adverse events.

Treatment options available for patients with relapsed/refractory follicular lymphoma in later-line settings and factors that impact the selection of a PI3K inhibitor over other types of therapies.

Recommendations for appropriately assessing patients with follicular lymphoma with disease progression after frontline treatment and options to consider as second-line therapy.

The panelists discuss the phase 3 INVICTUS trial of ripretinib and the phase 1 study of ripretinib intra-patient dose escalation.

Third-line treatment recommendations for patients with GIST and a discussion on side effect management.

Frontline treatment options available to treat newly diagnosed follicular lymphoma, based on a patient’s presentation, and recommendations for offering maintenance therapy following first-line treatment.

Important considerations when diagnosing follicular lymphoma, including the rationale for assessing patients’ FLIPI score and looking for any signs of histologic transformation.

Experts discuss the considerations of lines of therapy, comment on molecular testing, and the role of repeat biopsies.

The experts discuss a case presentation of a 66-year-old woman with heavily pretreated GIST, and comment on follow-up times and treatment options.

Prior to discussing treatment options for a 71-year-old woman with relapsed/refractory follicular lymphoma, John P. Leonard, MD, of Weill Cornell Medicine and NewYork-Presbyterian Hospital, sets the stage with an overview of the patient’s case.

Experts review 3 clinical cases, discuss treatment options and relevant clinical trials in GIST.

Hematology/oncology expert, John P. Leonard, MD, describes the rationale for treating an elderly patient with relapsed/refractory follicular lymphoma with a PI3K inhibitor in the third-line setting.

Luca Bertamini, MD, a hematologist oncologist at the Università delgi Studi di Torino, discusses outcomes and prognosis for patients with high-risk multiple myeloma.

Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.

Leora Horn, MD, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.

Yi-Bin Chen, MD, comments on the need for improvements in patient assessment tools, measurements of response, and therapeutic agents for the management of acute GvHD in the future.

Yi-Bin Chen, MD, considers potential treatment options for steroid-refractory aGvHD and examines the results of the phase 3 REACH2 study of ruxolitinib.